Drug Trial Radar · NCT05532722
ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Sep 28, 2022
Primary completion
Aug 28, 2025
Study completion Mar 31, 2026
Sponsor
- Lead sponsor
- Abcuro, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
Conditions
- T-cell Large Granular Lymphocytic Leukemia
Interventions
ABC008Drug
Given subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, nature, and severity of treatment-emergent AEs and SAEs as determined by NCI CTCAE v5.0Time frame: Through Study Completion an average of 48 weeks
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Duarte, California
University of Southern California
Los Angeles, California
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Icahn School of Medicine at Mount Sinai
New York, New York
Cleveland Clinic Foundation
Cleveland, Ohio
The University of Texas M.D. Anderson Cancer Center
Houston, Texas
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.